Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 12/20 | 0.36 |
| ▸ | NPY1R | P25929 | 9/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.36 |
| ▸ | NPY2R | P49146 | 5/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20104610 | 0.84 | MEN1 (0.36) | KISS1RMEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL20099658 | 0.84 | MEN1 (0.38) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL23436545 | 0.83 | MEN1 (0.35) | KISS1RMEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL23436544 | 0.82 | MEN1 (0.37) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL7935092 | 0.81 | MEN1 (0.44) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL21973636 | 0.80 | NPY4R (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL20763852 | 0.80 | NPY4R (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL11980626 | 0.79 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL13347956 | 0.78 | ALOX15 (0.35) | KISS1RMEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL18758145 | 0.77 | NPY4R (0.41) | KISS1RNPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-26 | — | — | US | disclosed |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-28 | — | — | US | disclosed |
| US-20210253661-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2021-08-19 | — | — | US | disclosed |
| US-20210163566-A1 | Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-03 | — | — | US | disclosed |
| US-20200283491-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253661-A1 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | GLP1R, GIPR, IAPP | KISS1R 249/4885MEN1 1397/4885CYP1A2 4757/4885 |
| US-20200283491-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | KISS1R 228/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | KISS1R 228/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-20210163566-A1 | Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors | NPY1R, NPY5R, NPY2R | KISS1R 228/4885MEN1 1303/4885CYP1A2 4749/4885 |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | KISS1R 228/4885MEN1 1303/4885CYP1A2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.